M&T Bank Corp Oric Pharmaceuticals, Inc. Transaction History

M&T Bank Corp

$30.1 Billion
Q3 2024

A detailed history of M&T Bank Corp transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, M&T Bank Corp holds 85,137 shares of ORIC stock, worth $695,569. This represents 0.0% of its overall portfolio holdings.

Number of Shares

85,137

Previous 85,137 -0.0%

Holding current value

$695,569

Previous $872,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$7.52 - $11.9 $103,106 - $163,160	13,711 Added 19.2%	85,137 $872,000
Q2 2024 Jul 31, 2024	BUY	$6.63 - $12.93 $139 - $271	21 Added 0.03%	71,426 $504,000
Q1 2024 May 07, 2024	SELL	$8.04 - $16.03 $100,668 - $200,711	-12,521 Reduced 14.92%	71,405 $981,000
Q4 2023 Feb 06, 2024	BUY	$5.41 - $9.43 $70,124 - $122,231	12,962 Added 18.27%	83,926 $772,000
Q3 2023 Nov 02, 2023	BUY	$6.05 - $9.28 $629 - $965	104 Added 0.15%	70,964 $429,000
Q2 2023 Aug 09, 2023	BUY	$4.95 - $8.4 $350,757 - $595,224	70,860 New	70,860 $549,000
Q1 2022 May 09, 2022	SELL	$4.54 - $16.1 $93,233 - $330,629	-20,536 Closed	0 $0
Q4 2021 Feb 07, 2022	BUY	$12.01 - $20.3 $70,871 - $119,790	5,901 Added 40.32%	20,536 $302,000
Q3 2021 Oct 28, 2021	BUY	$15.9 - $25.22 $232,696 - $369,094	14,635 New	14,635 $306,000
Q2 2021 Aug 13, 2021	SELL	$17.37 - $25.34 $158,987 - $231,937	-9,153 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$20.32 - $39.8 $22,473 - $44,018	1,106 Added 13.74%	9,153 $310,000
Q3 2020 Nov 06, 2020	BUY	$19.5 - $31.26 $34,749 - $55,705	1,782 Added 28.44%	8,047 $201,000
Q2 2020 Jul 29, 2020	BUY	$25.68 - $38.12 $160,885 - $238,821	6,265 New	6,265 $211,000

Others Institutions Holding ORIC

# of Institutions

124

Shares Held

66.6M

Call Options Held

7.8K

Put Options Held

700

View Full List

About Oric Pharmaceuticals, Inc.

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $323M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

More about ORIC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.

Account